Clinical trial
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
Abstract
The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Keywords
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
This study's objects
Directly linked records, matched by DOI, trial reference, or registry, not just topic.
Publications from this trial
ArticlePsilocybin
Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.
ArticlePsilocybin
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.
ArticlePsilocybin
Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study.
ArticlePsilocybin
Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression.
Related research
ArticlePsilocybin
Association of Psilocybin Use in Adolescents with Major Depressive Episode
ArticlePsilocybin
Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.
ArticlePsilocybin